Stryker Currently Down Seven Consecutive Days, On Track for Longest Losing Streak Since September 2022 — Data Talk
Stryker Corporation (SYK) is currently at $333.10, down $2.93 or 0.87%
--Would be lowest close since Jan. 30, 2024, when it closed at $316.64
--Currently down eight of the past nine days
--Currently down seven consecutive days; down 5.08% over this period
--Longest losing streak since Sept. 27, 2022, when it fell for eight straight trading days
--Worst seven day stretch since the seven days ending Oct. 4, 2023, when it fell 7.37%
--Down 6.92% month-to-date
--Up 11.23% year-to-date
--Down 7.14% from its all-time closing high of $358.71 on March 27, 2024
--Up 10.26% from 52 weeks ago (April 20, 2023), when it closed at $302.10
--Down 7.14% from its 52-week closing high of $358.71 on March 27, 2024
--Up 31.22% from its 52-week closing low of $253.85 on Oct. 12, 2023
--Traded as low as $330.50; lowest intraday level since Jan. 30, 2024, when it hit $314.05
--Down 1.65% at today's intraday low
All data as of 11:07:24 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 18, 2024 11:25 ET (15:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts